Background This study aimed to determine the prevalence of Antimicrobial Resistance
Genes (ARGs), with a focus on colistin resistance in clinical A. baumannii, as well as the risk …

Background and Aim: Colistin is increasingly being used as a “last-line” therapy to treat
infections caused by multidrug-resistant (MDR) Acinetobacter baumannii isolates, when …

Colistin is one of the most effective alternatives for treating Acinetobacter baumannii
infections. The aim of this study was to determine colistin resistance and heteroresistance …

Background We investigated the presence of heteroresistance against both tigecycline and
colistin in Acinetobacter baumannii and then evaluated the effectiveness of combined …

The emergence of extensive drug-resistant (XDR) Acinetobacter baumannii limits the
therapeutic options and leads to high mortality in intensive care units. Combined antibiotic …

Colistin and tigecycline are the only therapeutic options for extensively drug resistant
Acinetobacter baumannii (XDR-AB), but there is little comparative study. This retrospective …

Introduction The development of colistin resistance in Acinetobacter baumannii during
treatment has been identified in certain patients, often leading to prolonged or recurrent …

Multidrug-resistant (MDR) Acinetobacter baumannii (A. baumannii) bacterium, a nosocomial
pathogen associated with a high mortality rate and limited therapeutic options have …

Objective Nosocomial infection caused by carbapenem-resistant Acinetobacter baumannii is
a worldwide problem and treatment options remain controversial. This study investigated the …

Introduction Acinetobacter baumannii antimicrobial resistance is a public health concern in
developing and developed countries, especially in the hospital setting. Understanding the …